Fig. 4
A-366 alters the cell cycle state of growing and differentiating MEL erythroid cells. Agent concentration for all panels, unless indicated differently: HMBA (5 × 10− 3 M), A-366 and SGC2097 (10− 6 M), UNC0642 (1.6 × 10− 6 M). a MEL cells were treated for 48 h with drug combinations indicated in the graph. Total RNA isolation was performed, and RNA was processed with cDNA synthesis and qPCR analysis of the β-globin transcripts. Data was normalized to β-actin expression and analyzed according to the 2−ΔΔCt method. **p < 0.001; *p < 0.01; Student’s t-test. b MEL cells were treated for 48 h with the indicated drug combinations in the graph, before total protein isolation was performed. Western blot with specific antibodies against β-globin and β-tubulin is shown. *p < 0.05; Student’s t‐test. c Flow cytometry analysis of the indicated in the graph drug combinations for 24 h, 48 h and/or 72 h. Graph shows the distribution of single cells (MEL cells) into the phases of the cell cycle. Data in all panels represent means ± standard deviation